Global Information
회사소개 | 문의 | 위시리스트

전신홍반루푸스(SLE) : 역학 예측(2028년)

Systemic Lupus Erythematosus (SLE) - Epidemiology Forecast - 2028

리서치사 DelveInsight Business Research LLP
발행일 2019년 11월 상품 코드 535000
페이지 정보 영문 92 Pages
가격
US $ 3,250 ₩ 3,831,000 PDF by E-mail (Single User License)
US $ 6,500 ₩ 7,662,000 PDF by E-mail (Site License)
US $ 9,750 ₩ 11,493,000 PDF by E-mail (Global License)


전신홍반루푸스(SLE) : 역학 예측(2028년) Systemic Lupus Erythematosus (SLE) - Epidemiology Forecast - 2028
발행일 : 2019년 11월 페이지 정보 : 영문 92 Pages

주요 7개국(미국, 영국, 독일, 프랑스, 이탈리아, 스페인, 일본)에서 전신홍반루푸스(SLE : Systemic Lupus Erythematosus)의 2017년 이환 수는 981만 9,080명으로 추산되고 있습니다.

주요 7개국(미국, 영국, 독일, 프랑스, 이탈리아, 스페인, 일본)의 전신홍반루푸스(SLE) 시장을 조사했으며, 질병 개요, 역학적 예측, 성별·연령·병형별 유병 수의 추이와 예측, 미충족 요구, 시장 성장요인 및 장벽 등을 정리하여 전해드립니다.

목차

제1장 주요 인사이트

제2장 전신홍반루푸스(SLE) : 환자 개요

  • 환자 분포(실수치)
  • 환자 분포(예측)

제3장 질병 배경과 개요 : 전신홍반루푸스(SLE)

  • 서론
  • 위험인자
  • 원인
  • 증상
  • 임상 증상
  • 병원
  • 치료 및 진단에서 사용되는 생물학적 제제 및 바이오마커
  • 진단
  • 분류

제4장 역학과 환자 인구

  • 주요 조사 결과
  • 주요 7개국의 전신홍반루푸스(SLE)
  • 주요 7개국 전신홍반루푸스(SLE)의 총유병 수
  • 미국
    • 가정과 이론적 근거
    • 전신홍반루푸스(SLE)의 유병 수
    • 전신홍반루푸스(SLE)의 유병 수 : 성별
    • 전신홍반루푸스(SLE)의 유병 수 : 연령별
    • 전신홍반루푸스(SLE)의 유병 수 : 병형별
  • EU 5개국 전신홍반루푸스(SLE)의 역학
    • 가정과 이론적 근거
    • 독일
      • 가정과 이론적 근거
      • 전신홍반루푸스(SLE)의 유병 수
      • 전신홍반루푸스(SLE)의 유병 수 : 성별
      • 전신홍반루푸스(SLE)의 유병 수 : 연령별
      • 전신홍반루푸스(SLE)의 유병 수 : 병형별
    • 프랑스
    • 이탈리아
    • 스페인
    • 영국
  • 일본
    • 가정과 이론적 근거
    • 전신홍반루푸스(SLE)의 유병 수
    • 전신홍반루푸스(SLE)의 유병 수 : 성별
    • 전신홍반루푸스(SLE)의 유병 수 : 연령별
    • 전신홍반루푸스(SLE)의 유병 수 : 병형별

제5장 미충족 요구

제6장 시장 성장요인

제7장 시장 장벽

제8장 KOL의 견해

제9장 부록

  • 조사 방법

제10장 DelveInsight의 서비스 내용

제11장 면책사항

제12장 DelveInsight 소개

KSA 19.11.08

이 페이지에 게재되어 있는 내용은 최신판과 약간 차이가 있을 수 있으므로 영문목차를 함께 참조하여 주시기 바랍니다. 기타 자세한 사항은 문의 바랍니다.

List of Tables

  • Table 1: Major clinical manifestations of Systemic Lupus Erythematosus (SLE)
  • Table 2: Summary of key pathogenic processes, cells, and molecules in SLE
  • Table 3: Differential Diagnosis of Systemic Lupus Erythematosus
  • Table 4: Diagnostic criteria for Systemic Lupus Erythematosus
  • Table 5: Classification criteria for Systemic Lupus Erythematosus
  • Table 6: Total Diagnosed Prevalent cases of SLE in 7MM (2017-2028)
  • Table 7: Total Diagnosed Prevalent Cases of SLE in the US (2017-2028)
  • Table 8: Gender -Specific Prevalent Cases of SLE in the US (2017-2028)
  • Table 9: Severity Specific Prevalent Cases of SLE in the US (2017-2028)
  • Table 10: Total Diagnosed Prevalent Cases of SLE in Germany (2017-2028)
  • Table 11: Gender Specific Prevalent Cases of SLE in Germany (2017-2028)
  • Table 12: Severity Specific Prevalent Cases of SLE in Germany (2017-2028)
  • Table 13: Total Diagnosed Prevalent Cases of SLE in France (2017-2028)
  • Table 14: Gender Specific Prevalent Cases of SLE in France (2017-2028)
  • Table 15: Severity Specific Prevalent Cases of SLE in France (2017-2028)
  • Table 16: Total Diagnosed Prevalent Cases of SLE in Italy (2017-2028)
  • Table 17: Gender Specific Prevalent Cases of SLE in Italy (2017-2028)
  • Table 18: Severity Specific Prevalent Cases of SLE in Italy (2017-2028)
  • Table 19: Total Diagnosed Prevalent Cases of SLE in Spain (2017-2028)
  • Table 20: Gender Specific Prevalent Cases of SLE in Spain (2017-2028)
  • Table 21: Severity Specific Prevalent Cases of SLE in Spain (2017-2028)
  • Table 22: Total Diagnosed Prevalent Cases of SLE in the UK (2017-2028)
  • Table 23: Gender Specific Prevalent Cases of SLE in the UK (2017-2028)
  • Table 24: Severity Specific Prevalent Cases of SLE in the UK (2017-2028)
  • Table 25: Total Diagnosed Prevalent Cases of SLE in Japan (2017-2028)
  • Table 26: Gender Specific Prevalent Cases of SLE in Japan (2017-2028)
  • Table 27: Severity Specific Prevalent Cases of SLE in Japan (2017-2028)

List of Figures

  • Figure 1: Management of Systemic Lupus Erythematosus
  • Figure 2: Risk Factors of SLE
  • Figure 3: T-cell Signaling and Gene regulation in SLE
  • Figure 4: Role of Innate Cells (Neutrophils, Macrophages, and Dendritic Cells) in SLE
  • Figure 5: Algorithm for the diagnosis of Systemic Lupus Erythematosus
  • Figure 6: Total Diagnosed Prevalent cases of SLE in 7MM (2017-2028)
  • Figure 7: Total Diagnosed Prevalent Cases of SLE in the US (2017-2028)
  • Figure 8: Gender -Specific Cases of SLE in the US (2017-2028)
  • Figure 9: Severity Specific Cases of SLE in the US (2017-2028)
  • Figure 10: Total Diagnosed Prevalent Cases of SLE in Germany (2017-2028)
  • Figure 11: Gender -Specific Cases of SLE in Germany (2017-2028)
  • Figure 12: Severity Specific Cases of SLE in Germany (2017-2028)
  • Figure 13: Total Diagnosed Prevalent Cases of SLE in France (2017-2028)
  • Figure 14: Gender Specific Cases of SLE in France (2017-2028)
  • Figure 15: Severity Specific Cases of SLE in France (2017-2028)
  • Figure 16: Total Diagnosed Prevalent Cases of SLE in Italy (2017-2028)
  • Figure 17: Gender Specific Cases of SLE in Italy (2017-2028)
  • Figure 18: Severity Specific Cases of SLE in Italy (2017-2028)
  • Figure 19: Total Diagnosed Prevalent Cases of SLE in Spain (2017-2028)
  • Figure 20: Gender Specific Cases of SLE in Spain (2017-2028)
  • Figure 21: Severity Specific Cases of SLE in Spain (2017-2028)
  • Figure 22: Total Diagnosed Prevalent Cases of SLE in the UK (2017-2028)
  • Figure 23: Gender Specific Cases of SLE in the UK (2017-2028)
  • Figure 24: Severity Specific Cases of SLE in the UK (2017-2028)
  • Figure 25: Total Diagnosed Prevalent Cases of SLE in Japan (2017-2028)
  • Figure 26: Gender Specific Cases of SLE in Japan (2017-2028)
  • Figure 27: Severity Specific Cases of SLE in Japan (2017-2028)
  • Figure 29: Unmet need: Failure of Numerous clinical trials
  • Figure 30: Unmet Need: Complexity in Pathophysiology of the diseases
  • Figure 31: Steps to fulfill the current unmet need
  • Figure 32: Market Drivers
  • Figure 33:Market Barriers

DelveInsight's 'Systemic Lupus Erythematosus (SLE)-Epidemiology Forecast-2028' report delivers an in-depth understanding of the disease, historical & forecasted epidemiology trends of Systemic Lupus Erythematosus in the United States, EU5 (Germany, Spain, Italy, France, and the United Kingdom), and Japan.

Geography Covered

  • The United States
  • EU5 (Germany, France, Italy, Spain, and the United Kingdom)
  • Japan

Study Period: 2017-2028

Systemic Lupus Erythematosus -Disease Understanding

According to the American College of Rheumatology "Systemic lupus erythematosus, referred to as SLE or lupus, is a chronic (long-term) disease that causes systemic inflammation which affects multiple organs. In addition to affecting the skin and joints, it can affect other organs in the body such as the kidneys, the tissue lining the lungs (pleura), heart (pericardium), and brain." Many patients experience fatigue, weight loss, and fever.

SLE is most commonly seen in women in the reproductive age group (frequently starting at childbearing age), although lupus is increasingly recognized after the age of 40 years, particularly in the Europeans. The disease is prone to relapses and remissions, resulting in considerable morbidity due to flares of disease activity and accumulated organ damage, and an increased risk of premature death, mostly due to infection or cardiovascular disease.

Systemic Lupus Erythematosus -Epidemiology

The Systemic Lupus Erythematosus epidemiology division provides insights about historical and current patient pool and forecasted trends for every seven major countries. It helps to recognize the causes of current and forecasted trends by exploring numerous studies and views of key opinion leaders. This part of the DelveInsight report also provides the diagnosed patient pool and their trends along with assumptions undertaken.

The disease epidemiology covered in the report provides historical as well as forecasted epidemiology (Total Diagnosed Prevalent cases, Gender-Specific Prevalence, and Severity-Specific Prevalence(Mild, Moderate and Severe)) scenario of Systemic Lupus Erythematosus in the 7MM covering United States, EU5 countries (Germany, Spain, Italy, France and United Kingdom) and Japan from 2017 to 2028.

According to DelveInsight, the total Diagnosed Prevalent cases of Systemic Lupus Erythematosus (SLE) in the 7MM was found to be 484,213 in 2017. The prevalence of Systemic Lupus Erythematosus in the 7MM is expected to increase during the study period of 2017 to 2028.

Among 7MM, the United States has the highest prevalent population of Systemic Lupus Erythematosus with about 259,474 cases in 2017. Among EU-5 countries, UK had the highest number of prevalent cases with approximately 62,852 cases, followed by Italy in 2017. Germany had the least number of prevalent cases, while in Japan, the diagnosed prevalent population of Systemic Lupus Erythematosus was found to be approximately 58,168.

Systemic Lupus Erythematosus Report Insights

  • The report covers a descriptive overview of the Systemic Lupus Erythematosus, explaining its causes, risk factors, pathophysiology, and diagnosis.
  • Comprehensive insight has been provided into the epidemiology Systemic Lupus Erythematosus in the 7MM countries covering the United States, EU5 (Germany, France, Italy, Spain, and the United Kingdom), and Japan.
  • Assesses growth opportunities in 7MM countries with respect to the patient population.

Systemic Lupus Erythematosus Report Key Strengths

  • 10-Year Forecast
  • 7MM Coverage
  • Diagnosed Prevalent Patient Pool of Systemic Lupus Erythematosus
  • Gender-Specific Diagnosed Patient Pool of Systemic Lupus Erythematosus
  • Severity-Specific Diagnosed Patient Pool of Systemic Lupus Erythematosus

Systemic Lupus Erythematosus Report Assessment

  • Current Treatment Practices
  • Unmet Needs
  • Detailed Pipeline Product Profiles

Key Benefits

  • Key assessments
  • Patient Segmentation
  • Disease Risk & Burden
  • Risk of disease by type

Table of Contents

1. Key Insights

2. Systemic Lupus Erythematosus (SLE): Patient Overview at a Glance

  • 2.1. Total Patient Share (%) Distribution of SLE in 2017
  • 2.2. Total Patient Share (%) Distribution of SLE in 2028

3. Disease Background and Overview: Systemic Lupus Erythematosus (SLE)

  • 3.1. Introduction
  • 3.2. Risk Factors
  • 3.3. Causes
  • 3.4. Symptoms
  • 3.5. Clinical Manifestation
  • 3.6. Pathogenesis
  • 3.7. Biologics and Biomarkers in the Treatment and Diagnosis of SLE
  • 3.8. Diagnosis
    • 3.8.1. Recent classification of SLE

4. Epidemiology and Patient Population

  • 4.1. Key Findings
  • 4.2. Population and Forecast Parameters
  • 4.3. Total Diagnosed Prevalent cases of SLE in 7MM
  • 4.4. United States
    • 4.4.1. Assumptions and Rationale
    • 4.4.2. Total Diagnosed Prevalent cases of SLE in the US
    • 4.4.3. Gender Specific cases of SLE in the US
    • 4.4.4. Severity Specific cases of SLE in the US
  • 4.5. EU5
  • 4.6. Germany
    • 4.6.1. Assumptions and Rationale
    • 4.6.2. Total Diagnosed Prevalent cases of SLE in Germany
    • 4.6.3. Gender Specific cases of SLE in Germany
    • 4.6.4. Severity Specific cases of SLE in Germany
  • 4.7. France
    • 4.7.1. Assumptions and Rationale
    • 4.7.2. Total Diagnosed Prevalent cases of SLE in France
    • 4.7.3. Gender Specific cases of SLE in France
    • 4.7.4. Severity Specific cases of SLE in France
  • 4.8. Italy
    • 4.8.1. Assumptions and Rationale
    • 4.8.2. Total Diagnosed Prevalent cases of SLE in Italy
    • 4.8.3. Gender Specific cases of SLE in Italy
    • 4.8.4. Severity Specific cases of SLE in Italy
  • 4.9. Spain
    • 4.9.1. Assumptions and Rationale
    • 4.9.2. Total Diagnosed Prevalent cases of SLE in Spain
    • 4.9.3. Gender Specific cases of SLE in Spain
    • 4.9.4. Severity Specific cases of SLE in Spain
  • 4.10. United Kingdom
    • 4.10.1. Assumptions and Rationale
    • 4.10.2. Total Diagnosed Prevalent cases of SLE in the UK
    • 4.10.3. Gender Specific cases of SLE in the UK
    • 4.10.4. Severity Specific cases of SLE in the UK
  • 4.11. Japan
    • 4.11.1. Assumptions and Rationale
    • 4.11.2. Total Diagnosed Prevalent cases of SLE in Japan
    • 4.11.3. Gender Specific cases of SLE in Japan
    • 4.11.4. Severity Specific cases of SLE in Japan

5. Unmet Needs

6. Market Drivers

7. Market Barriers

8. KOL Views

9. Appendix

  • 9.1. Report Methodology

10. DelveInsight Capabilities

11. Disclaimer

12. About DelveInsight

Back to Top
전화 문의
F A Q